MADISON, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth, , announced today that the January issue of R&D Directions magazine has selected Wyeth as The Best Central Nervous System (CNS) Pipeline as part of the magazine's annual "Top 10 Pipeline Report."
Currently, Wyeth has 19 compounds in their CNS drug pipeline under development as potential treatments for patients with neurological conditions including schizophrenia, bipolar disorder, depression, Alzheimer's disease, neuropathic pain, fibromyalgia and acute stroke.
Wyeth is the only major pharmaceutical company exploring three technical platforms for Alzheimer's disease therapeutics: small molecules, biotechnology proteins and vaccines. As part of its "War on Alzheimer's Disease," Wyeth has 11 compounds in development including beta-amyloid inhibitors (in partnership with Elan Pharmaceuticals), gamma secretase inhibitors, plasminogen activator inhibitors and cognitive enhancers. Alzheimer's Disease is a devastating neurological disorder that is expected to affect more than 80 million people worldwide by 2040.
"Wyeth is honored to be selected as having this year's Best CNS pipeline by R&D Directions," says Robert R. Ruffolo, Jr., Ph.D., President, Wyeth Research and Development (R&D) and Senior Vice President, Wyeth. "Through ongoing investment in our people, technology and resources, Wyeth will ensure that our R&D pipeline continues to grow in breadth, depth and innovation to remain an industry leader."
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third party-payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "ITEM 1A, RISK FACTORS." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
WyethCONTACT: Media Contacts, Gerald Burr, Wyeth Pharmaceuticals,+1-484-865-5138, Gwen Fisher, Wyeth Pharmaceuticals, +1-484-865-5160; orInvestor Contact, Justin Victoria, Wyeth, +1-973-660-5340
Web site: http://www.wyeth.com/
